Towa PharmaceuticalTOWA PHARMACEUTICAL CO.,LTD.4553東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥8 is left as operating profit. Revenue changed +5.4% from the prior year, operating profit -0.6%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 9.6% | 0.50× | 4.8% | 2.57× | 12.3% |
| 2023 | 1.1% | 0.59× | 0.6% | 2.73× | 1.7% |
| 2024 | 7.1% | 0.57× | 4.0% | 2.97× | 12.0% |
| 2025 | 7.3% | 0.58× | 4.2% | 3.02× | 12.7% |
| 2026 | 1.9% | 0.58× | 1.1% | 2.99× | 3.3% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 165,615 | 208,859 | 227,934 | 259,594 | 273,710 |
| Cost of revenue | 95,429 | 136,145 | 146,551 | 164,865 | 174,606 |
| Gross profit | 70,185 | 72,713 | 81,383 | 94,729 | 99,104 |
| SG&A | 50,980 | 67,199 | 63,735 | 71,486 | 76,001 |
| Operating income | 19,205 | 5,514 | 17,647 | 23,242 | 23,102 |
| Pretax income | 22,246 | 4,605 | 24,459 | 26,330 | 13,165 |
| Income tax | 6,331 | 2,404 | 8,286 | 7,343 | 7,914 |
| Net income attributable to owners | 15,914 | 2,201 | 16,173 | 18,986 | 5,250 |
| Operating margin | 11.6% | 2.6% | 7.7% | 9.0% | 8.4% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥32.8B | ¥24.3B | ¥29.6B | ¥45.5B | ¥44.8B |
| Total assets | ¥332.1B | ¥371.3B | ¥430.7B | ¥470.8B | ¥475.3B |
| Net assets | ¥132.2B | ¥136.9B | ¥155.9B | ¥171.6B | ¥178.1B |
| Share capital | ¥4.72B | ¥4.72B | ¥4.72B | ¥4.72B | ¥4.72B |
| Trade receivables | ¥42.9B | ¥46.8B | ¥62.9B | ¥61.4B | ¥63.3B |
| Property, plant and equipment | ¥99.9B | ¥127B | ¥153.6B | ¥168.4B | ¥170.6B |
| Intangible assets excluding goodwill | ¥58.1B | ¥52.9B | ¥50.6B | ¥45.8B | ¥26.7B |
| Goodwill | ¥39.1B | ¥34.6B | ¥32.6B | ¥28.1B | ¥9.47B |
| Investment securities | ¥464M | ¥676M | ¥641M | ¥871M | ¥957M |
| Current assets | ¥166.9B | ¥183B | ¥217.7B | ¥247.3B | ¥267.3B |
| Current liabilities | ¥115.1B | ¥78.5B | ¥80.1B | ¥87.9B | ¥96.9B |
| Trade payables | ¥14.8B | ¥17.3B | ¥15.7B | ¥17.9B | ¥21.3B |
| Short-term borrowings | ¥49.3B | ¥3.68B | ¥3.11B | ¥4.7B | ¥7.1B |
| Long-term borrowings | ¥79.2B | ¥150.3B | ¥189.1B | ¥195.1B | ¥183.3B |
| Total liabilities | ¥199.9B | ¥234.5B | ¥274.8B | ¥299.2B | ¥297.2B |
| Equity attributable to owners of parent | ¥129.1B | ¥128.2B | ¥141.4B | ¥157.5B | ¥158.8B |
| Retained earnings | ¥122.1B | ¥121.2B | ¥134.5B | ¥150.5B | ¥151.8B |
| Treasury stock | -¥5.61B | -¥5.61B | -¥5.61B | -¥5.59B | -¥5.58B |
EDINET (FSA Japan)
有価証券報告書－第70期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第69期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第68期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第67期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第66期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第65期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.